Valiant Organics to buy 34.26% stake in Valiant Labs

Valiant Organics Limited has proposed the acquisition of 1,86,07,531 equity shares, representing a 34.26% stake, in Valiant Laboratories Limited . The shares will be purchased from Dhanvallabh Ventures LLP through an off-market transaction. This acquisition is part of a broader restructuring exercise being undertaken by Valiant Organics Limited and is subject to the receipt of requisite approvals.

The transaction is scheduled to take place any time after four working days from the date of intimation, which was May 19, 2026. The acquisition price will not exceed the limits provided in the proviso to Regulation 10(1)(a) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The volume weighted average market price for the 60 trading days preceding the notice was Rs. 62.71 per equity share.

Transaction Details and Rationale

The acquirer, Valiant Organics Limited, is a member of the promoter group of the target company. The proposed acquisition is exempt from making an open offer under Regulation 10(1)(a)(iii) of the Takeover Regulations. The rationale provided for this move is the ongoing restructuring exercise aimed at achieving strategic synergies.

Parameter	Details
Target Company	Valiant Laboratories Limited
Acquirer	Valiant Organics Limited
Seller	Dhanvallabh Ventures LLP
Shares to be Acquired	1,86,07,531
Stake Acquired	34.26%
VWAP (60 days)	Rs. 62.71 per share

Shareholding Pattern

Following the transaction, the shareholding structure of Valiant Laboratories Limited will undergo significant changes. Dhanvallabh Ventures LLP will see its holding reduce from 46.84% to 12.58%, while Valiant Organics Limited will emerge with a 34.26% stake.

Shareholder	Pre-Transaction Shares	Pre-Transaction %	Post-Transaction Shares	Post-Transaction %
Valiant Organics Limited	-	-	1,86,07,531	34.26
Dhanvallabh Ventures LLP	2,54,37,500	46.84	68,29,969	12.58

The Board of Directors of Valiant Laboratories Limited had previously accorded in-principle approval on May 16, 2026, to explore potential restructuring options. This evaluation was aimed at achieving operational, organizational, and strategic synergies. The current acquisition by the promoter group entity aligns with the board's objective of unlocking long-term value and enhancing the clarity of the business profile.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.74%	-4.78%	+14.33%	-1.34%	-27.38%	-51.95%

Valiant Laboratories Limited has published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in newspapers Financial Express (English) and Mumbai Lakshadeep (Marathi) on May 16, 2026, in compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were previously reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 14, 2026, in Mumbai. The intimation has also been uploaded on the company's website at www.valiantlabs.in .

Standalone Financial Performance

On a standalone basis, the company delivered a strong turnaround in FY26, swinging to a net profit of ₹554.82 lakhs compared to a net loss of ₹215.02 lakhs in the previous year. Revenue from operations rose significantly to ₹21,704.25 lakhs from ₹13,336.18 lakhs in FY25. For the quarter ended March 31, 2026, the standalone net profit stood at ₹353.28 lakhs on total income of ₹6,607.61 lakhs. The standalone results reflect a pre-tax profit of ₹754.79 lakhs for FY26, compared to a pre-tax loss of ₹144.78 lakhs in FY25.

Metric	Q4 FY26 (₹ Lakhs)	FY26 (₹ Lakhs)	Q4 FY25 (₹ Lakhs)	FY25 (₹ Lakhs)
Revenue from Operations	6,530.34	21,704.25	5,777.00	13,336.18
Total Income	6,607.61	21,993.73	5,842.39	13,878.99
Net Profit/(Loss) before Tax	473.49	754.79	392.36	(144.78)
Net Profit/(Loss) after Tax	353.28	554.82	323.83	(215.02)
Total Comprehensive Income	352.03	554.39	321.56	(217.28)
Basic EPS (₹)	0.65	1.02	0.74	(0.50)
Diluted EPS (₹)	0.70	1.10	0.74	(0.50)

Consolidated Financial Performance

On a consolidated basis, which includes subsidiary Valiant Advanced Sciences Private Limited, the group reported a net loss of ₹326.79 lakhs for FY26. Revenue from operations for the year increased to ₹23,746.75 lakhs. The consolidated results reflect higher costs associated with the subsidiary's operations, resulting in a net loss for the full year despite a profit of ₹175.87 lakhs in Q4 FY26. The consolidated pre-tax profit for the quarter stood at ₹104.68 lakhs.

Metric	Q4 FY26 (₹ Lakhs)	FY26 (₹ Lakhs)	Q4 FY25 (₹ Lakhs)	FY25 (₹ Lakhs)
Revenue from Operations	9,198.18	23,746.75	5,778.56	13,338.20
Total Income	9,215.30	23,978.79	5,547.10	13,881.68
Net Profit/(Loss) before Tax	104.68	76.82	93.91	(151.26)
Net Profit/(Loss) after Tax	175.87	(326.79)	70.36	(220.12)
Total Comprehensive Income	176.07	(326.37)	67.96	(222.52)
Basic EPS (₹)	0.32	(0.51)	0.16	(0.51)
Diluted EPS (₹)	0.35	(0.51)	0.16	(0.51)

Additional Financial Details

The paid-up equity share capital stood at ₹5,431.25 lakhs as of March 31, 2026, compared to ₹4,345.00 lakhs in the previous year, on both standalone and consolidated basis. Reserves excluding revaluation reserves as per the balance sheet stood at ₹26,544.62 lakhs (standalone) and ₹25,657.26 lakhs (consolidated) for FY26, against ₹19,093.31 lakhs and ₹19,086.01 lakhs respectively in FY25. The financial results have been prepared in accordance with Indian Accounting Standards (IndAS) as prescribed under Section 133 of the Companies Act, 2013, and are available on the BSE, NSE, and the company's website. The full format of the financial results is accessible at www.bseindia.com , www.nseindia.com , and www.valiantlabs.in .